Comparative Study on Surgical and Conservative Management of Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) in Disease Stage 2 |
Lee, Ho Kyung
(Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine)
Seo, Mi Hyun (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) Pang, Kang Mi (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) Song, Seung Il (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) Lee, Jeong Keun (Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou University School of Medicine) |
1 | Devogelaer JP. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000;12:331-5. DOI ScienceOn |
2 | Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-82. |
3 | Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. DOI ScienceOn |
4 | Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76. DOI ScienceOn |
5 | Khosla S, Burr D, Cauley J, et al ; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007;22:1479-91. DOI ScienceOn |
6 | Park YD, Kim YR, Kim DY, et al. Awareness of Korean dentists on bisphosphonate related osteonecrosis of the jaws: preliminary report. J Korean Assoc Oral Maxillofac Surg 2009;35:153-7. |
7 | Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11:S290-308. |
8 | Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate- related osteonecrosis of the jaw-2009 update. J Oral Maxillofac Surg 2009;67 Suppl 1:2-12. |
9 | The Korean Endocrine Society, The Korean Society of Bone Metabolism, The Korean Society of Osteoporosis, The Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ): position statement of Korea. J Korean Endocr Soc 2009;24:227-30. DOI ScienceOn |
10 | Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. DOI ScienceOn |
11 | Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:2644-8. DOI ScienceOn |
12 | Song JW, Kim KH, Song JM, et al. Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg 2011;37:1-8. 과학기술학회마을 DOI ScienceOn |
13 | Jeffcoat MK, Williams RC, Kaplan ML, Goldhaber P. Nuclear medicine techniques for the detection of active alveolar bone loss. Adv Dent Res 1987;1:80-4. DOI |
14 | Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167-73. DOI ScienceOn |
15 | Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. DOI ScienceOn |
16 | Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70. DOI ScienceOn |
17 | Ohmae M, Saito S, Morohashi T, et al. A clinical and histological evaluation of titanium mini-implants as anchors for orthodontic intrusion in the beagle dog. Am J Orthod Dentofacial Orthop 2001;119:489-97. DOI ScienceOn |
18 | Lee JK. Dental considerations of the bisphosphonate-related osteonecrosis of the jaw. Osteoporosis 2011;9:18-27. |
19 | Park YJ, Pyo SW, Kim JA, Min JK. A case of avascular necrosis of mandible associated with the use of bisphosphonate in a patient with rheumatoid arthritis and osteoporosis. J Korean Rheum Assoc 2006;13:150-4. |
20 | Marx RE, editor. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Hanover Park, IL: Quintessence Pub. Co.; 2007. |
21 | Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81. DOI ScienceOn |
22 | Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. DOI ScienceOn |
23 | Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011;47:191-4. DOI ScienceOn |
24 | Sarasquete ME, González M, San Miguel JF, García-Sanz R. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009;15:382-7. DOI ScienceOn |
25 | Chaudhry AN, Ruggiero SL. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofac Surg Clin North Am 2007;19:199-206. DOI ScienceOn |
26 | Thumbigere-Math V, Sabino MC, Gopalakrishnan R, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009;67:1904-13. DOI ScienceOn |
27 | Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. DOI ScienceOn |
28 | Tirelli G, Biasotto M, Chiandussi S, Dore F, De Nardi E, Di Lenarda R. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck 2009;31:1249-54. DOI ScienceOn |
29 | Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-50. DOI ScienceOn |
30 | You KH, Yoon KH, Bae JH, et al. Consideration for treatment of bisphosphonate-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 2010;36:206-10. 과학기술학회마을 DOI ScienceOn |
31 | Wutzl A, Biedermann E, Wanschitz F, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008;30:1224-30. DOI ScienceOn |
32 | Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):85-95. |
33 | Black DM, Schwartz AV, Ensrud KE, et al ; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. DOI |